Efficacy of intraarticular combined injection of platelet-rich plasma and botulinum toxin versus platelet-rich plasma monotherapy for knee osteoarthritis: A randomized superiority trial

Not Applicable

Recruiting

• Conditions: Musculoskeletal Diseases

• Registration Number: PACTR202109625368648
• Lead Sponsor: Mansoura university hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-09-08
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Age of 40–70 years old
Suffering from knee pain in the past six months
History of complaints for at least one month
The need for painkillers
Knee osteoarthritis was confirmed by radiography (Kellgren-Lawrence classification grade 2–3).

Exclusion Criteria

presence of systemic disorders (ie, diabetes mellitus, immunodeficiency, and collagen vascular diseases)
the history of malignancy, the
history of autoimmune diseases or platelet disorders,
body mass index of over 33 kg/m2,
the presence of IAIs within the past three months before the injection,
the history of a recently occurred severe knee trauma, knee septic arthritis, the active ulcer or septic arthritis of the knee, genu varum or valgum of over 20°,
history of clinically significant cardiac, hepatic, renal, or neurological dysfunction,
coagulopathy,
known allergy to study drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The reduction of pain and an improvement of function after intraarticular injections

Secondary Outcome Measures

Name	Time	Method
patients’ satisfaction